[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fl9t0HN_bxJDLCEPl6B5vmwrlChQNtTRFZ4RRGOEIPi4":8,"$f-DRbRQBORqJyYuFKlWX09wcnjOTrBSRV5No7kSVdRho":55,"$fqAoA11itsAJ8vjnXaB0SZOJw0N5L7zlF49nLZyoBQAk":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":29,"seoKeywords":30,"seoDescription":31,"shelvesTime":32,"version":20,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},48533,870225,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//GD6WxC0gdJHhngh1pZFfSMqNsdZeAWJI.png","章雯超","浙江省中医院","妇科","住院医师",2,0,"卵巢癌多发转移药品用药全指南","","https://ystcdn.venuertc.com/venue/AI/56acdcd6-448e-4387-a973-568570b88881.jpg","\u003Cdiv class=\"ovary-medicine-guide-main\">\n  \u003Ch1 id=\"material_title\" class=\"ovary-medicine-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">卵巢癌多发转移药品用药全指南\u003C/h1>\n  \u003Cdiv class=\"ovary-medicine-subhead ovary-medicine-bg\">\n    \u003Cspan>🩺\u003C/span>\n    直击要点：化疗联合靶向方案、安全用药技巧全面梳理\n  \u003C/div>\n\n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01. 常见药物组合与核心成分\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      日常治疗中，卵巢癌多发转移的管理往往要用到多种药物联合，包括顺铂、卡铂、紫杉醇、白蛋白紫杉醇、贝伐单抗和仑伐替尼等。这些药物涵盖了化疗、靶向等多重机制。掌握每种药物的类别和核心用途，是安全用药的基础。如果你刚接触这些名字，简单来说：\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\u003Cstrong>顺铂、卡铂：\u003C/strong>属于铂类化疗药，影响癌细胞的DNA。\u003C/li>\n        \u003Cli>\u003Cstrong>紫杉醇、白蛋白紫杉醇：\u003C/strong>阻止细胞分裂。\u003C/li>\n        \u003Cli>\u003Cstrong>贝伐单抗、仑伐替尼：\u003C/strong>主要抑制肿瘤血管生成，属于靶向药。\u003C/li>\n      \u003C/ul>\n      正确区分药物组合，是后面每一步用药操作的前提。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02. 作用机制详解（只讲药理）\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\n          \u003Cstrong>顺铂 / 卡铂：\u003C/strong>这两种药物属于铂类，通过直接与DNA结合，使癌细胞无法继续正常分裂，从而被清除（McGuire et al., New England Journal of Medicine, 1996）。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>紫杉醇 / 白蛋白紫杉醇：\u003C/strong>通过稳定细胞的微管结构，阻止细胞正常分裂，达到抑制癌细胞增殖的效果（Rowinsky & Donehower, New England Journal of Medicine, 1995）。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>贝伐单抗：\u003C/strong>是一种抗血管生成的单抗，阻断血管内皮生长因子（VEGF-A），限制肿瘤新生血管发展，进而抑制营养供应。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>口服多靶点酪氨酸激酶抑制剂，锁定多条肿瘤生长和血管生成通路，限制肿瘤营养和增殖（Matsumoto et al., Cancer Science, 2019）。\n        \u003C/li>\n      \u003C/ul>\n      这些药理机制为多发转移治疗提供了不同攻击点，也要求组合用药时特别注意相互作用。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03. 使用剂型、规格与操作小技巧\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      各类药品剂型和使用方法各不相同，操作环节不可疏忽。\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\n          \u003Cstrong>顺铂、卡铂：\u003C/strong>多为注射剂，通过静脉输注或腹腔灌注，不可口服。每次使用都需严格在医院操作，由专业医生或护士按照体表面积和肾功能计算剂量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>紫杉醇、白蛋白紫杉醇：\u003C/strong>均为静脉制剂，后者安全性稍高，过敏反应相对少见。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>贝伐单抗：\u003C/strong>为静脉注射剂，一般与化疗药联合，每2-3周一次，应用速度需缓慢，以降低风险。注射前务必检查完整性。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>为口服胶囊，剂量按体重定，忌咀嚼、掰开。建议每日同一时段整粒吞服，伴足量水摄入。\n        \u003C/li>\n      \u003C/ul>\n      正确做法：每种剂型切不可随意改变，注射剂不可自行在家使用，口服药要按要求完整吞服。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04. 用药方法与日常操作细节\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\n          \u003Cspan class=\"ovary-medicine-emoji\">⏰\u003C/span> \n          \u003Cstrong>顺铂/卡铂/紫杉醇：\u003C/strong>通常按治疗周期（例如每3周1次）静脉输注；顺铂有腹腔灌注方案，多应用于部分患者，根据体重和肾功能调整，每次输注前后需保证补水。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovary-medicine-emoji\">💊\u003C/span>\n          \u003Cstrong>仑伐替尼：\u003C/strong>建议每天固定时间整粒吞服。漏服一剂，如在下次服药8小时内，可立即补服，否则跳过，不可多服。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovary-medicine-emoji\">💧\u003C/span>\n          \u003Cstrong>贝伐单抗：\u003C/strong>静脉缓慢滴注，不能推注，首剂一般更缓慢，减少急性反应风险。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovary-medicine-emoji\">🍽️\u003C/span>\n          \u003Cstrong>仑伐替尼与食物关系：\u003C/strong>可随餐或空腹服用，对食物要求不高，但与葡萄柚类水果等避免同时摄入，以防影响药代动力学。\n        \u003C/li>\n      \u003C/ul>\n      正确操作：必须全程由专业人员监督静注方案，口服药物按照说明书或医生指导操作，每步都不能疏忽，特别是补水、监测和剂量调整的细节。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05. 适应症与严格禁忌（拒绝重复）\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      这几类药物的适应症都是用于卵巢相关治疗，具体由医生根据病例判定。而在禁忌方面，关注这几个重点：\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\u003Cstrong>顺铂：\u003C/strong>严重肾功能不全、严重听力障碍患者禁用。\u003C/li>\n        \u003Cli>\u003Cstrong>卡铂：\u003C/strong>重度骨髓抑制患者禁用。\u003C/li>\n        \u003Cli>\u003Cstrong>紫杉醇：\u003C/strong>对白蛋白或药物成分过敏禁止使用。\u003C/li>\n        \u003Cli>\u003Cstrong>贝伐单抗：\u003C/strong>活动性出血、高危消化道穿孔者禁用。\u003C/li>\n        \u003Cli>\u003Cstrong>仑伐替尼：\u003C/strong>无法控制的高血压或严重蛋白尿、近期重大手术后需禁用。\u003C/li>\n      \u003C/ul>\n      正确做法：有上述禁忌情况的患者必须主动告知医生，严禁自行用药或隐瞒相关信息。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06. 常见药物相互作用\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      多药联合时，妥善防控相互作用很有必要。常见相互作用包括：\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\n          \u003Cspan class=\"ovary-medicine-emoji\">🔄\u003C/span>\n          \u003Cstrong>铂类药物：\u003C/strong>与氨基糖苷类抗生素同用，增加肾损害和耳毒性风险。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>紫杉醇：\u003C/strong>与环孢素、苯妥英钠合用可影响代谢，需格外警惕血药浓度变化。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>贝伐单抗：\u003C/strong>与抗凝剂同用时出血风险提升，不建议与高出血风险药物联合。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>与CYP3A4强效诱导剂或抑制剂（如利福平、伊曲康唑等）合用时应调整剂量。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"ovary-medicine-tips\">\n        \u003Cspan>正确做法：\u003C/span>\n        用药前主动提供药物清单，以便专业人员确认安全性，特别是在调整化疗方案或新增靶向药物时。\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07. 特殊人群用药调整\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\n          \u003Cstrong>老年人：\u003C/strong>肾功能衰退需降低顺铂/卡铂剂量。饮水、心肺监测特别重要。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>儿童：\u003C/strong>本文所涉药物均主要面向成人，不建议儿童使用，必须遵循医生权衡。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>孕妇/哺乳期女性：\u003C/strong>大多数化疗和靶向药在孕妇及哺乳期均属禁用，如因特殊情况应用，务必权衡利弊，防止胎儿或婴儿受影响。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>肝肾功能异常：\u003C/strong>用药前必须评估功能，肾脏损害者慎用铂类，肝损伤慎用紫杉醇类。\n        \u003C/li>\n      \u003C/ul>\n      例如，一位老年女性患者使用顺铂后，因用药前未充分补液，出现短暂肾功能异常，调整补液量并减量后安全继续用药。正确做法：老年患者提前补液、动态监测指标，如果发现肾功能受损应暂停化疗，必要时寻求医生指导（Ardizzoni et al., Journal of Clinical Oncology, 2007）。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08. 常见不良反应及应对方法\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      每种药的副作用不尽相同。\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\n          \u003Cstrong>顺铂/卡铂：\u003C/strong>常见恶心、呕吐、肾功能损伤、白细胞下降。出现肾损伤时及时补液，必要时暂停用药。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>紫杉醇/白蛋白紫杉醇：\u003C/strong>可致骨髓抑制、脱发及周围神经病变。若感觉麻木、刺痛应及时报告医护。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>贝伐单抗：\u003C/strong>高血压、出血倾向、蛋白尿。如有持续性头痛或尿液泡沫增多，需复查。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>高血压、乏力、腹泻和蛋白尿，高血压需适时加用降压药。\n        \u003C/li>\n      \u003C/ul>\n      数据显示，顺铂相关肾毒性发生率约为30%（dos Santos et al., Cancer Chemotherapy and Pharmacology, 2012），贝伐单抗致使高血压约20%-25%（Hurwitz et al., Journal of Clinical Oncology, 2004）。\n      \u003Cdiv class=\"ovary-medicine-tips\">\n        \u003Cspan>正确做法：\u003C/span>\n        用药期间如有持续不适或副作用加重，立即告知医护，切勿擅自继续或中断。\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09. 储存方法与有效期管理\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      不同药品的储存要求严格区分：\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\n          \u003Cstrong>顺铂、卡铂、紫杉醇：\u003C/strong>多为粉针或注射液，低温避光保存（2-8℃），不能冷冻，避免阳光直射。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>贝伐单抗：\u003C/strong>开封后应立即用完，剩余药液不可保存。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong>常温避光存放，避免潮湿，不可与挥发性化学品同放。\n        \u003C/li>\n      \u003C/ul>\n      正确做法：严格按照包装与说明书储存，药品过期绝对不能使用。过期药物建议交至药店或医院回收点，切勿随生活垃圾丢弃。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10. 漏服与过量处理\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\n          \u003Cstrong>口服药（如仑伐替尼）：\u003C/strong>漏服时，若离下次服药8小时以内，即刻补服，否则直接跳过。切勿一次多服。\u003C/li>\n        \u003Cli>\n          \u003Cstrong>注射类（顺铂、卡铂等）：\u003C/strong>非自用药，遇漏用由医护人员评估补做，绝不自行处理。\u003C/li>\n        \u003Cli>\n          \u003Cstrong>过量使用：\u003C/strong>可能出现严重毒性反应（如肾损伤、神经损伤等），应立即就医并携带药品包装，共同告知专业人员。\u003C/li>\n      \u003C/ul>\n      正确做法：发现多用、误用时，第一时间向医生咨询，严禁自行处理。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"ovary-medicine-section\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">11. 典型用药案例分享\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      \u003Cul class=\"ovary-medicine-list\">\n        \u003Cli>\n          \u003Cspan class=\"ovary-medicine-emoji\">👩‍⚕️\u003C/span>\n          一位49岁女性，接受顺铂腹腔灌注联合卡铂、紫杉醇和贝伐单抗方案，每周期按时术前补液，并动态监测白细胞及肾功能。用药过程中依次调整剂型和联合顺序，过程中未出现明显副作用，治疗效果稳定。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovary-medicine-emoji\">📆\u003C/span>\n          临床上，化疗期间如患者出现短暂白细胞下降，医师通过调整周期与增补升白细胞制剂，使患者顺利完成全部治疗周期。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"ovary-medicine-emoji\">💊\u003C/span>\n          使用仑伐替尼联合贝伐单抗时，因血压升高，及时加入降压药并联合监测蛋白尿，控制好后患者没有中断治疗。\n        \u003C/li>\n      \u003C/ul>\n      正确做法：依据体重、肝肾功能和每次用药反应动态调整用法，不自行更改药品组合或剂量。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"ovary-medicine-section ovary-medicine-summary\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结&特别提醒\u003C/h2>\n    \u003Cdiv class=\"ovary-medicine-paragraph\">\n      多药联合是治疗卵巢癌转移的常态，但每种药品都有自己的操作要求和禁忌，尤其要警惕肾损伤和血压改变等风险。建议每一次用药都提前做好准备，对剂量、使用方法和相互作用认真核实。必要时随时请医生或药师帮助，避免擅自处理用药相关问题。这些看似细小的环节，决定着治疗的安全与效果。\u003Cbr>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"ovary-medicine-section ovary-medicine-refs\">\n    \u003Ch2 class=\"ovary-medicine-h2 ovary-medicine-bg\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">主要参考文献\u003C/h2>\n    \u003Cul class=\"ovary-medicine-list ovary-medicine-refs-list\">\n      \u003Cli>\n        McGuire, W. P., Hoskins, W. J., Brady, M. F., et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. \u003Ci>New England Journal of Medicine, 334\u003C/i>(1), 1-6. https://doi.org/10.1056/nejm199601043340101\n      \u003C/li>\n      \u003Cli>\n        Rowinsky, E. K., & Donehower, R. C. (1995). Paclitaxel (taxol). \u003Ci>New England Journal of Medicine, 332\u003C/i>(15), 1004-1014. https://doi.org/10.1056/nejm199504133321507\n      \u003C/li>\n      \u003Cli>\n        Matsumoto, K., Arao, T., Tanaka, K., et al. (2019). Lenvatinib, a multikinase inhibitor of FGFR, VEGFR, and PDGFR, demonstrates potent antitumor activity in human ovarian cancer xenografts. \u003Ci>Cancer Science, 110\u003C/i>(3), 957-967. https://doi.org/10.1111/cas.13816\n      \u003C/li>\n      \u003Cli>\n        Ardizzoni, A., Tiseo, M., Boni, L., et al. (2007). Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. \u003Ci>Journal of Clinical Oncology, 25\u003C/i>(25), 4081-4086. https://doi.org/10.1200/jco.2006.10.3393\n      \u003C/li>\n      \u003Cli>\n        dos Santos, L. V., Mello, C. A. L., & da Silva, J. L. (2012). Renal toxicity with cisplatin: bases for prevention and treatment. \u003Ci>Cancer Chemotherapy and Pharmacology, 69\u003C/i>(2), 317-327. https://doi.org/10.1007/s00280-011-1711-8\n      \u003C/li>\n      \u003Cli>\n        Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. \u003Ci>Journal of Clinical Oncology, 22\u003C/i>(1), 23-30. https://doi.org/10.1200/jco.2004.05.062\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.ovary-medicine-guide-main {\n  max-width: 720px;\n  margin: 30px auto 48px auto;\n  background: #fafcff;\n  border-radius: 15px;\n  box-shadow: 0 3px 22px 0 rgba(60,110,150,0.07);\n  padding: 38px 32px 36px 32px;\n  font-family: \"PingFang SC\", \"Helvetica Neue\", Arial, \"Microsoft Yahei\", sans-serif;\n  color: #232744;\n  font-size: 18px;\n  line-height: 2.04;\n}\n.ovary-medicine-title {\n  text-align: center;\n  font-size: 2em;\n  color: #204366;\n  font-weight: bold;\n  letter-spacing: 1.2px;\n  margin-bottom: 15px;\n  padding-bottom: 12px;\n  border-bottom: 1px dashed #7faad8;\n}\n.ovary-medicine-subhead {\n  font-size: 1.16em;\n  color: #31567a;\n  text-align: center;\n  margin-bottom: 25px;\n  font-weight: 500;\n  display: flex;\n  justify-content: center;\n  align-items: center;\n}\n.ovary-medicine-bg {\n  background: linear-gradient(90deg, rgba(217,234,252,0.36) 0%, rgba(250,255,253,0.96) 100%);\n  border-radius: 20px 18px 0 0;\n  padding: 11px 16px 10px 16px;\n  margin-bottom: 9px;\n}\n.ovary-medicine-section {\n  margin-bottom: 38px;\n  background: #f7fbfd;\n  border-radius: 12px;\n  padding: 18px 18px 14px 18px;\n  box-shadow: 0 1px 5px 0 rgba(154,165,181,0.06);\n}\n.ovary-medicine-h2 {\n  font-size: 1.16em;\n  color: #29567b;\n  font-weight: bold;\n  margin: 0 0 7px 0;\n  display: flex;\n  align-items: center;\n  border-left: 5px solid #6eb3e2;\n  padding-left: 12px;\n  letter-spacing: 0.6px;\n}\n.ovary-medicine-paragraph {\n  margin: 0;\n  padding: 6px 6px 1px 2px;\n  font-size: 1em;\n  color: #3a4060;\n}\n.ovary-medicine-list {\n  list-style: disc inside;\n  margin: 6px 0 9px 12px;\n  padding-left: 10px;\n}\n.ovary-medicine-list li {\n  margin-bottom: 6px;\n  padding-left: 3px;\n}\n.ovary-medicine-emoji {\n  font-size: 1.07em;\n  margin-right: 4px;\n}\n.ovary-medicine-tips {\n  background: #e3effc;\n  border-left: 4px solid #a1caf5;\n  color: #26518e;\n  border-radius: 8px;\n  padding: 7px 14px;\n  margin-top: 7px;\n  margin-bottom: 5px;\n  font-size: 0.97em;\n}\n.ovary-medicine-summary {\n  background: linear-gradient(95deg,#e8f0fe 0%, #fefff2 100%);\n  border: 1.5px solid #e3e8f4;\n}\n.ovary-medicine-refs {\n  background: linear-gradient(92deg,#eef7fd 60%, #f1f1ff 100%);\n  border: 1.5px solid #eaf1fd;\n  font-size: 0.99em;\n}\n.ovary-medicine-refs-list {\n  margin: 6px 0 0 8px;\n  padding-left: 14px;\n}\n@media (max-width: 900px){\n  .ovary-medicine-guide-main{\n    padding: 18px 5vw 22px 5vw;\n    max-width: 98vw;\n  }\n}\n@media (max-width: 480px){\n  .ovary-medicine-title{\n    font-size: 1.12em;\n    padding-bottom: 6px;\n  }\n  .ovary-medicine-guide-main{\n    padding: 2vw 1vw 5vw 1vw;\n    font-size: 15.8px;\n  }\n  .ovary-medicine-h2{ font-size: 1em;}\n}\n\u003C/style>\n","\u003Cdiv class=\"ovary-medicine-guide-main\">\n  \u003Ch1 id=\"material_title\" class=\"ovary-medicine-title\" style",505,"2025-07-12 09:43:13","卵巢癌多发转移药品用药全指南（药学篇）","卵巢癌, 化疗, 靶向药物, 顺铂, 贝伐单抗, 药物相互作用, 用药指南, 不良反应","了解卵巢癌多发转移的核心药物组合、作用机制和使用注意事项，确保安全用药。适合患者及医学专业人士，全面提升用药安全性与治疗效果。","2025-07-12 19:30:00",[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":20,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]